Hepatitis A vaccine inactivated - Beijing Minhai BiotechnologyAlternative Names: HAV inactivated vaccine - Beijing Minhai Biotechnology; Inactivated Hepatitis A vaccine - Beijing Minhai Biotechnology
Latest Information Update: 01 Sep 2015
At a glance
- Originator Beijing Minhai Biotechnology
- Class Hepatitis A vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Hepatitis A
Most Recent Events
- 01 Sep 2015 Phase-III clinical trials in Hepatitis A (Prevention) in China (Parenteral) before September 2015